Lutetium-177 (often called Lu-177) revolutionizes targeted cancer treatment. Doctors use it in radioligand therapy for specific tumors.
This isotope binds to cancer cells precisely. It delivers beta radiation directly to them. Consequently, it kills malignant cells while sparing most healthy tissue.
In prostate cancer, Lu-177 targets PSMA (prostate-specific membrane antigen). PSMA appears highly on metastatic castration-resistant prostate cancer cells. Therefore, Pluvicto (Lu-177 vipivotide tetraxetan) attacks advanced cases effectively.
Patients receive intravenous infusions every 6 weeks. Typically, they get up to 6 cycles. Moreover, doctors first confirm PSMA expression via a PET scan.
This therapy extends survival noticeably. It also reduces pain and improves quality of life. For instance, recent FDA expansions allow earlier use—before chemotherapy in suitable cases.
Additionally, Lu-177 dotatate treats neuroendocrine tumors (NETs). It binds to somatostatin receptors on gastroenteropancreatic NETs. As a result, it controls tumor growth well in progressive cases.
Treatment shows strong efficacy. Many patients achieve tumor shrinkage or stable disease. Furthermore, progression-free survival improves significantly compared to older options.
Side effects remain generally manageable. Common issues include fatigue, dry mouth, nausea, and decreased appetite. However, doctors monitor blood counts closely because mild anemia or low platelets can occur.
Kidney function requires protection too. Patients stay hydrated and follow protocols. Importantly, severe toxicities happen infrequently.
Overall, Lu-177 offers hope for hard-to-treat cancers. Researchers continue exploring combinations and earlier use. Thus, this approach keeps advancing rapidly in oncology.